

EDITORIAL

A Balancing Act: GRHL3 Limits WNT Signaling to Promote Tissue Homeostasis in the Esophageal Epithelium

Tissue homeostasis requires a balance between cellular proliferation and differentiation, and its disruption often manifests in disease. Understanding the tight regulation between cellular proliferation and differentiation holds promise to uncover innovative approaches to treating diseases in which the balance is altered, including cancer. Grainy head like 3 (GRHL3) is a member of a family of transcription factors highly conserved from *Drosophila* through humans.¹ Previous studies revealed critical roles for GRHL3 in epidermal development and skin barrier formation showing that GRHL3 is crucial for maintaining epidermal tissue homeostasis.²⁻⁴ In GRHL3-deficient skin and oral epithelium, hyperproliferation ensues, rendering these tissues highly susceptible to chemically induced carcinogenesis.^{5,6} Notably, tissue-specific pathways govern GRHL3's tumor suppressive functions in these tissues, with malignancy mediated by a GRHL3/PTEN/AKT proto-oncogene axis in skin⁶ and a GRHL3/GSK3 β /c-Myc axis in the oral epithelium.⁵ The function of GRHL3 in the esophageal epithelium had not been explored. In this issue of *Cellular and Molecular Gastroenterology and Hepatology*, Georgy et al⁷ discover a novel GRHL3 tumor suppressive mechanism active in the esophagus by which loss of GRHL3 disrupts the proliferation/differentiation balance in stratified squamous epithelium pushing it toward proliferation and leading to esophageal squamous cell carcinoma (ESCC).

Using a mouse constitutive *Grhl3* knockout model, the authors assessed the function of GRHL3 first in the developing esophagus. Cellular proliferation was enhanced in knockout esophageal epithelium leading to a thickening of embryonic esophageal epithelium. These results indicate that in the developing esophagus, GRHL3 loss disrupts the proliferation/differentiation balance. To study GRHL3 function in the mature, adult esophageal epithelium, the team developed a conditional *Grhl3* knockout model with deletion controlled by ED-L2-Cre. Like the embryonic tissue, GRHL3 disruption in the mature tissue compromised the proliferation/differentiation balance, skewing the tissue toward a hyperproliferative state. To assess the potential for GRHL3 to act as a tumor suppressor in the esophagus, the authors used the chemical carcinogen 4-nitroquinolene-1 oxide (4-NQO) to induce ESCC in wild-type and *Grhl3* conditional knockout mice. Strikingly, *Grhl3* conditional knockout mice treated with 4-NQO quickly lost substantial amounts of weight. Large, occluding SCCs were present by 26 weeks, compared with wild-type mice, which developed smaller, nonoccluding SCCs. Histologic scoring identified a predominance of SCC, papillomas, and dysplasia in tumors from *Grhl3*-cKO mice, whereas wild-type tissue predominantly consisted of hyperplasia. These observations show

that GRHL3 functions as a tumor suppressor in the esophageal epithelium and that its deletion promotes ESCC by increasing the cancer susceptibility of deficient cells.

To elucidate the molecular mechanism through which GRHL3 suppresses cancer, Georgy et al⁷ took the logical approach of identifying genes with altered transcription in the absence of GRHL3. They applied rigorous criteria to their transcriptome analysis to define bona fide GRHL3-mediated pathways disrupted in esophageal cancer. By comparing expression profiles among baseline tissues and tumor tissues from wild-type mice and conditional knockout mice, the investigators identified the HOP homeobox (HOPX) protein as significantly downregulated in both groups. HOPX had previously been proposed as a tumor suppressor in ESCC⁸ and in head and neck SCC.⁹ To pin down GRHL3 as a direct regulator of HOPX, the group performed chromatin immunoprecipitation and identified GRHL3 occupancy at the *Hopx* gene in esophageal cells. Their transcriptome and pathway analysis further revealed dysregulated WNT signaling in GRHL3-deficient tumors, an interesting finding given that HOPX deletion expands WNT signaling in cardiomyocytes.¹⁰ Using chromatin immunoprecipitation, HOPX was shown to occupy the *Wnt2* and *Wnt9a* genes, both upregulated in GRHL3-deficient tumors, and the *Met* gene, a WNT pathway transcriptional target. Consistent with WNT activation, a marked increase in nuclear β -catenin occurred in tumors from *Grhl3* conditional knockout mice. Interestingly, WNT2 and WNT9A are also dysregulated in head and neck SCC.¹¹ A crucial component of this study was substantiating their observations from mice in human esophageal squamous cell tumors. Pairwise comparisons of more than 50 tumor and matched normal samples revealed a highly significant correlation between *GRHL3* and *HOPX*, with both being downregulated in tumor tissue. Accordingly, *WNT2*, *WNT9A*, and *MET* were consistently upregulated in tumors. Consistent with the transcriptome analysis, immunohistochemical analysis of patient tumors showed GRHL3 and HOPX protein loss in tumors and induction of WNT9A. A dramatic increase in nuclear β -catenin staining confirmed hyperactivation of WNT signaling in GRHL3-deficient human ESCC tissue.

Taken together, Georgy et al⁷ identify a GRHL3/HOPX/WNT axis active in esophageal squamous cells that regulates the balance between cellular proliferation and differentiation. When disrupted, cellular proliferation becomes unrestrained, promoting tumorigenesis. The study mechanistically links GRHL3, HOPX, and WNT, each of which had previously been implicated independently in SCC.^{8,9,11} There is an urgent need for innovative, efficacious ESCC therapies, and this study supports WNT inhibition as a

117 promising approach to treat esophageal tumors with
 118 reduced GRHL3 protein. A next step toward this goal would
 119 include testing Food and Drug Administration-approved
 120 WNT inhibiting drugs in *Grhl3* conditional knockout mice
 121 treated with 4-NQO. Finally, acknowledging that WNT-based
 122 therapies are challenging because of the essential role of
 123 WNT in stem cells, the GRHL3/HOPX/WNT axis identified
 124 here could be further explored to uncover a more refined
 125 set of ESCC-specific targets for therapeutic interventions.

127 OLIVIA D. FRANKLIN, MS
 128 MICHELE A. BATTLE, PhD
 129 Department of Cell Biology
 130 Q6 Neurobiology, and Anatomy
 131 Medical College of Wisconsin
 132 Milwaukee, Wisconsin
 133

134 Q5 References

- 135 1. Ting SB, et al. The identification and characterization of
 136 human Sister-of-Mammalian Grainyhead (SOM) expands
 137 the grainyhead-like family of developmental transcription
 138 factors. *Biochem J* 2003;370:953–962. 187
- 139 2. Ting SB, et al. A homolog of *Drosophila* grainy head is
 140 essential for epidermal integrity in mice. *Science* 2005;
 141 308:411–413. 188
- 142 3. Ting SB, et al. The epidermis of *grhl3*-null mice displays
 143 altered lipid processing and cellular hyperproliferation.
 144 *Organogenesis* 2005;2:33–35. 189
- 145 4. Yu Z, et al. The Grainyhead-like epithelial transactivator Get-
 146 1/*Grhl3* regulates epidermal terminal differentiation and in-
 147 teracts functionally with LMO4. *Dev Biol* 2006;299:122–136. 190
- 148 5. Georgy SR, et al. Identification of a novel proto-
 149 oncogenic network in head and neck squamous cell
 150 carcinoma. *J Natl Cancer Inst* 2015;107:djv152. 191
- 151 6. Darido C, et al. Targeting of the tumor suppressor
 152 GRHL3 by a miR-21-dependent proto-oncogenic
 153 network results in PTEN loss and tumorigenesis. *Cancer*
 154 *Cell* 2011;20:635–648. 192
- 155 7. Georgy SR, et al. Identification of a novel GRHL3/HOPX/
 156 Wnt/ β -Catenin proto-oncogenic axis in squamous cell
 157 carcinoma of the esophagus. *Cell Mol Gastroenterol*
 158 *Hepatol* 2022;XX:XXX–XXX. 193
- 159 8. Yamashita K, et al. HOP/OB1/NECC1 promoter DNA is
 160 frequently hypermethylated and involved in tumorigenic
 161 ability in esophageal squamous cell carcinoma. *Mol*
 162 *Cancer Res* 2008;6:31–41. 194
- 163 9. Yap LF, et al. HOPX functions as a tumour suppressor in
 164 head and neck cancer. *Sci Rep* 2016;6:38758. 195
- 165 10. Jain R, et al. Integration of Bmp and Wnt signaling by
 166 Hopx specifies commitment of cardiomyoblasts. *Science*
 167 2015;348:aaa6071. 196
- 168 11. Aditya J, Smiline Girija AS, Paramasivam A, et al. Genetic
 169 alterations in Wnt family of genes and their putative as-
 170 sociation with head and neck squamous cell carcinoma.
 171 *Genomics Inform* 2021;19:e5. 197

Correspondence

Address correspondence to: Michele A. Battle, PhD, Department of Cell
 Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, 8701
 Watertown Plank Road, Milwaukee, Wisconsin 53226. e-mail: Q2
 mbattle@mcw.edu. 191

Conflicts of interest

The authors disclose no conflicts. Q3 193

© 2023 The Authors. Published by Elsevier Inc. on behalf of the AGA
 Institute. This is an open access article under the CC BY-NC-ND license
 (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). 195

2352-345X 196

<https://doi.org/10.1016/j.jcmgh.2023.01.011> 197